A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy

- Finnegan, Robert N., Reynolds, Hayley M., Ebert, Martin A., Sun, Yu, Holloway, Lois, Sykes, Jonathan R., Dowling, Jason, Mitchell, Catherine, Williams, Scott G., Murphy, Declan G., Haworth, Annette

[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Sandhu, Shahneen, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A., Williams, Scott G., Iravani, Amir, Martin, Andrew J., Davis, Ian D., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

- Kneebone, Andrew, Fraser-Browne, Carol, Duchesne, Gillian M., Fisher, Richard, Frydenberg, Mark, Herschtal, Alan, Williams, Scott G., Brown, Chris, Delprado, Waeick, Haworth, Annette, Joseph, David J., Martin, Jarad M., Matthews, John H. L., Millar, Jeremy L., Sidhom, Milllar, Spry, Nigel, Tang, Colin I., Turner, Sandra, Wiltshire, Kirsty L., Woo, Henry H., Davis, Ian D., Lim, Tee S., Pearse, Maria